GE Medical Systems has signed licensing agreements with the Texas A&M University system and Beth Israel Deaconess Medical Center to develop new near-infrared-light imaging technologies. Efforts will focus on assessing the potential of these technologies
GE Medical Systems has signed licensing agreements with the Texas A&M University system and Beth Israel Deaconess Medical Center to develop new near-infrared-light imaging technologies. Efforts will focus on assessing the potential of these technologies to improve the detection, diagnosis, and treatment of cancers. The licensing agreements call for GE to work with the research institutions to advance technologies there for eventual FDA approval.
The A&M system technology, fluorescence-enhanced optical imaging and tomography, combines imaging sensitivity, tissue penetration, and tissue characterization as the means to detect and track disease progression. It also might be used in the development of new diagnostic and therapeutic agents. The Beth Israel Deaconess technology is an intraoperative near-infrared fluorescence imaging system that enables surgeons to visualize surgical anatomy and functional fluorescence simultaneously, noninvasively, and with high spatial resolution. Potential applications include image-guided sentinel lymph node mapping, image-guided cancer resection with real-time assessment of surgical margins, mapping of tumor and normal vasculature, image-guided avoidance of critical structures such as nerves, and detection of occult metastases.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.